Company news

Newron Pharmaceuticals S.p.A. news in 2025

Newron Pharmaceuticals S.p.A.'s news releases, calls and decks from 2025, newest first.

View company

Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week

December 22, 2025

Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)

December 8, 2025

Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025

October 2, 2025

Newron presents H1 2025 results and provides business update

September 16, 2025

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)

September 5, 2025

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)

August 12, 2025

Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction

August 11, 2025

Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)

May 12, 2025

Newron Presents 2024 Financial Results and Provides 2025 Outlook

April 1, 2025

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman

March 24, 2025

Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference

March 11, 2025

Decks in 2025